SCHEMBL3240177

SCHEMBL3240177

CN(C)c1ccc(-c2[c]ccc(CNc3ccc(C(F)(F)F)cc3)c2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS1 P29475 1/20 0.41
CACNA1B Q00975 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C19 P33261 1/20 0.39
PPARA Q07869 2/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
KDM1A O60341 1/20 0.38
ALDH1A1 P00352 3/20 0.38
MAPT P10636 3/20 0.38
LMNA P02545 2/20 0.38
HTT P42858 2/20 0.38
GFER P55789 2/20 0.38
KMT2A Q03164 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
KDM4E B2RXH2 1/20 0.38
TP53 P04637 1/20 0.38
FFAR1 O14842 3/20 0.38
GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3245006 0.84 RHOC (0.44) CYP3A4CYP2C19PPARAMAPTTP53
SCHEMBL856260 0.79 CA1 (0.56) NOS1CACNA1BCA1CA2CA9
SCHEMBL3251941 0.79 KMT2A (0.43) NOS1CYP3A4CYP2C19ALDH1A1MAPT
SCHEMBL3246732 0.76 FFAR1 (0.45) CACNA1BCYP3A4CYP2C19PPARAMAPT
SCHEMBL3246486 0.74 FFAR1 (0.46) CACNA1BCYP3A4CYP2C19PPARAMAPT
SCHEMBL10449130 0.71 APP (0.46) CYP3A4ALDH1A1MAPTTDP1KDM4E
SCHEMBL26268446 0.70 RORC (0.48) CACNA1BCYP3A4CYP2C19CA1CA2
SCHEMBL3246798 0.69 FFAR1 (0.55) CACNA1BPPARACA1CA2ALDH1A1
SCHEMBL3104491 0.69 KCNQ2 (0.52) CYP3A4CYP2C19PPARAALDH1A1MAPT
SCHEMBL11671967 0.68 KIF11 (0.59) KDM1AALDH1A1MAPTKIF11MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2185149-A1 USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED H. Lundbeck A/S (DK) 2010-05-19 EP disclosed
WO-2009015667-A1 USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED H. LUNDBECK A/S (DK) 2009-02-05 WO disclosed